{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:16:01Z","timestamp":1762866961814},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T00:00:00Z","timestamp":1475539200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00134-016-4572-4","type":"journal-article","created":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T17:53:16Z","timestamp":1475603596000},"page":"233-236","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of severe MRSA infections: current practice and further development"],"prefix":"10.1007","volume":"43","author":[{"given":"Jos\u00e9-Artur","family":"Paiva","sequence":"first","affiliation":[]},{"given":"Philippe","family":"Eggimann","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,10,4]]},"reference":[{"key":"4572_CR1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00134-006-0470-5","volume":"33","author":"MDMF Gatte de","year":"2007","unstructured":"de Gatte MDMF, Revilla N, Calvo MV, Dominquez-Gil A, Sanchez-Navarro A (2007) Pharmacokinetic\/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 33:279\u2013285","journal-title":"Intensive Care Med"},{"key":"4572_CR2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotscahfer JC, Moellering RC et al (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49:325\u2013327","journal-title":"Clin Infect Dis"},{"key":"4572_CR3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"SJ Hal Van","year":"2012","unstructured":"Van Hal SJ, Lodise TP, Paterson DL (2012) The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 54:755\u2013771","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4572_CR4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/infdis\/jir270","volume":"204","author":"NE Holmes","year":"2011","unstructured":"Holmes NE, Turnidge JD, Munckhof WJ et al (2011) Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 204(3):340\u2013347","journal-title":"J Infect Dis"},{"issue":"1","key":"4572_CR5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","volume":"67","author":"MA Cataldo","year":"2012","unstructured":"Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N (2012) Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 67(1):17\u201324","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"4572_CR6","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE et al (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52(3):e18\u2013e55","journal-title":"Clin Infect Dis"},{"issue":"5","key":"4572_CR7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","volume":"54","author":"RG Wunderink","year":"2012","unstructured":"Wunderink RG, Niederman MS, Kollef MH et al (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54(5):621\u2013629","journal-title":"Clin Infect Dis"},{"issue":"9","key":"4572_CR8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s10096-013-1867-z","volume":"32","author":"H Jiang","year":"2013","unstructured":"Jiang H, Tang RN, Wang J (2013) Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomized controlled trials. Eur J Clin Microbiol Infect Dis 32(9):1121\u20131128","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4572_CR9","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","volume":"56","author":"KP Murray","year":"2013","unstructured":"Murray KP, Zhao JJ, Davis SL et al (2013) Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration\u00a0>\u00a01\u00a0mg\/L: a matched cohort study. Clin Infect Dis 56:1562\u20131569","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4572_CR10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2013.05.005","volume":"42","author":"IM Gould","year":"2013","unstructured":"Gould IM, Mir\u00f3 JM, Rybak MJ (2013) Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 42(3):202\u2013210","journal-title":"Int J Antimicrob Agents"},{"key":"4572_CR11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2334-11-279","volume":"11","author":"ML Schweizer","year":"2011","unstructured":"Schweizer ML, Furuno JP, Harris AD et al (2011) Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin susceptible Staphylococcus aureus bacteremia. BMC Infect Dis 11:279","journal-title":"BMC Infect Dis"},{"key":"4572_CR12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-0034-1397040","volume":"36","author":"NE Holmes","year":"2015","unstructured":"Holmes NE, Tong SYC, Davis JS, van Hal SJ (2015) Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond. Semin Respir Crit Care Med 36:17\u201330","journal-title":"Semin Respir Crit Care Med"},{"key":"4572_CR13","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00134-014-3323-7","volume":"40","author":"P Montravers","year":"2014","unstructured":"Montravers P, Dupont H, Bedos J-P et al (2014) Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. Intensive Care Med 40:988\u2013997","journal-title":"Intensive Care Med"},{"key":"4572_CR14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/AAC.01204-13","volume":"58","author":"TJ Dilworth","year":"2014","unstructured":"Dilworth TJ, Ibrahim O, Hall P, Sliwinski J et al (2014) \u03b2-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother 58:102\u2013109","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4572_CR15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","volume":"62","author":"JS Davis","year":"2016","unstructured":"Davis JS, Sud A, O\u2019Sullivan MV, Robinson JO et al (2016) Combination of vancomycin and \u03b2-Lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis 62(2):173\u2013180","journal-title":"Clin Infect Dis"},{"issue":"6","key":"4572_CR16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ijantimicag.2011.05.003","volume":"38","author":"Y Gillet","year":"2011","unstructured":"Gillet Y, Dumitrescu O, Tristan A, Dauwalder O et al (2011) Pragmatic management of Panton-Valentine leukocidin-associated staphylococcal diseases. Int J Antimicrob Agents 38(6):457\u2013464","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"4572_CR17","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1093\/cid\/ciw245","volume":"63","author":"B Fran\u00e7ois","year":"2016","unstructured":"Fran\u00e7ois B, Chastre J, Eggiman P, Laterre PF et al (2016) The SAATELLITE and EVADE clinical studies within the COMBACTE consortium: a public-private collaborative effort in designing and performing clinical trials for novel antibacterial drugs to prevent nosocomial pneumonia. Clin Infect Dis 63(Suppl 2):S46\u2013S51","journal-title":"Clin Infect Dis"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-016-4572-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00134-016-4572-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-016-4572-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T00:19:57Z","timestamp":1498349997000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00134-016-4572-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["4572"],"URL":"https:\/\/doi.org\/10.1007\/s00134-016-4572-4","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,4]]}}}